MetaVia Inc.
MTVA
Peringkat dalam Saham
#32611
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a... Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Harga Saham
$1.37
Kapitalisasi Pasar
$9.03M
Perubahan (1 hari)
2.24%
Perubahan (1 tahun)
-15.95%
Negara
US
Perdagangan MetaVia Inc. (MTVA)
Kategori
Healthcare
Riwayat harga saham MetaVia Inc. (MTVA)
Harga penutupan tertinggi: $2.19 pada 2024-12-01
Harga penutupan terendah: $60.07K pada 2016-08-01
Harga penutupan terendah: $60.07K pada 2016-08-01
Riwayat harga saham MetaVia Inc. dari 2016 hingga 2026
Performa harga saham tahunan
| Tahun | Performa |
|---|---|
| 2024 | -41.80% |
| 2023 | -64.19% |
| 2022 | -96.91% |
| 2021 | -75.22% |
| 2020 | -26.05% |
| 2019 | -64.56% |
| 2018 | -89.12% |
| 2017 | -4.63% |
| 2016 | 0.00% |
Harga saham perusahaan atau pesaing serupa
| Perusahaan | Harga saham | Perubahan 1th% | Negara |
|---|---|---|---|
| $534.12 | 25.25% |
US
|
|
| $231.12 | 760.78% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $880.75 | 8.18% |
NL
|
|
| $289.51 | 1.72% |
BE
|
